COPENHAGEN -- The 2022 European Alliance of Associations for Rheumatology (EULAR 2022) European Congress of Rheumatology kicked off its four day-run on Wednesday.

Many multinational pharmaceutical companies, including Celltrion of Korea, joined the convention, setting up booths to introduce the latest data on rheumatology and autoimmune disease treatments.

Despite the waning attention to Covid-19, EULAR organizers started this year's meeting with strict protocols regarding health and safety matters by checking the vaccination certifications of participants and operating a checkpoint that exhibitors and visitors go through before attending the conference for their safety.

Korea Biomedical Review glanced at Korean and foreign companies' booths exhibiting at the EULAR 2022 meeting and captured other scenes. EULAR 2022 officially opened on Wednesday and will continue through Saturday at the Bella Center in Copenhagen, Denmark.

On Wednesday, exhibitors and visitors go through security checkpoints at the EULAR 2022 meeting at the Bella Center in Copenhagen, Denmark. Exhibitors and visitors were also ｒｅｑｕｉｒｅd to show proof of vaccination to enter the venue.
On Wednesday, exhibitors and visitors go through security checkpoints at the EULAR 2022 meeting at the Bella Center in Copenhagen, Denmark. Exhibitors and visitors were also ｒｅｑｕｉｒｅd to show proof of vaccination to enter the venue.

 

Exhibitors and visitors print out their badges before entering the convention.
Exhibitors and visitors print out their badges before entering the convention.

 

Celltrion, the only Korean company to have a booth at EULAR 2022, touted the superiority of its biosimilar during the conference. The company is pushing to expand the market share of Remsima SC, its subcutaneous type infliximab biosimilar. This year, the company will present new data showing that the subcutaneous infliximab type had a statistically greater clinical outcome improvement than the intravenous infliximab type in patients with rheumatoid arthritis.
Celltrion, the only Korean company to have a booth at EULAR 2022, touted the superiority of its biosimilar during the conference. The company is pushing to expand the market share of Remsima SC, its subcutaneous type infliximab biosimilar. This year, the company will present new data showing that the subcutaneous infliximab type had a statistically greater clinical outcome improvement than the intravenous infliximab type in patients with rheumatoid arthritis.

 

AbbVie has one of the largest booths at the conference. The company's booth was crowded with EULAR members wanting to learn about Rinvoq, a Janus kinase (JAK) inhibitor used to treat chronic inflammatory disorders. This year, the company plans to present two study results using the treatment for ankylosing spondylitis and a series of post-hoc data on existing studies during EULAR.
AbbVie has one of the largest booths at the conference. The company's booth was crowded with EULAR members wanting to learn about Rinvoq, a Janus kinase (JAK) inhibitor used to treat chronic inflammatory disorders. This year, the company plans to present two study results using the treatment for ankylosing spondylitis and a series of post-hoc data on existing studies during EULAR.

 

Janssen has shown exciting strides in the field of psoriatic arthritis. This year, the company emphasized the DISCOVER-2 study, which showed the 100-week data for treating psoriatic arthritis patients with its interleukin-23 (IL-23) inhibitor Tremfya. The company began to receive reimbursement for the treatment in Korea in May.
Janssen has shown exciting strides in the field of psoriatic arthritis. This year, the company emphasized the DISCOVER-2 study, which showed the 100-week data for treating psoriatic arthritis patients with its interleukin-23 (IL-23) inhibitor Tremfya. The company began to receive reimbursement for the treatment in Korea in May.

 

Lilly showed off its strength in treating axial spondylarthritis with Taltz by unveiling the results of the COAST study with three-year follow-up data. The study involving 932 patients showed that 60 percent who had received at least one dose of Taltz completed the three-year therapy follow-up, with disease control maintained for some time on various efficacy scales.
Lilly showed off its strength in treating axial spondylarthritis with Taltz by unveiling the results of the COAST study with three-year follow-up data. The study involving 932 patients showed that 60 percent who had received at least one dose of Taltz completed the three-year therapy follow-up, with disease control maintained for some time on various efficacy scales.

 

Novartis also presented a study treating axial spondylarthritis with Cosentyx. The study showed that Cosentyx can significantly reduce the severity of nr-axSpA symptoms in most patients at one year and that this improvement is sustained for up to two years.
Novartis also presented a study treating axial spondylarthritis with Cosentyx. The study showed that Cosentyx can significantly reduce the severity of nr-axSpA symptoms in most patients at one year and that this improvement is sustained for up to two years.

 

Copyright © KBR Unauthorized reproduction, redistribution prohibited